2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

112. Thalassemia and Globin Gene Regulation: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Processes, Hematopoiesis, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Research, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

2899 Luspatercept in adults with transfusion-dependent α-thalassemia hemoglobin H disease: primary efficacy and safety data from a phase 2, double-blind, randomized, placebo-controlled, multicenter trial

Antonis Kattamis, MD, Vip Viprakasit2, Qin Liu3, Xiaolin Yin4, Meng-Yao Lu, MD5, Ying Dong6, Gian Luca Forni, MD7, Paolo Ricchi8, Ling Jiang9, Giovanni Battista Ferrero10, Sophia Delicou11, Shi Tao12, Guyun Wang13, Ying Zhao14, Alexandros Spyridonidis15, Kitty Formentin16, Iryna Bluemmert17, Vincent Jaquet18, Loyse Felber Medlin, PhD19, Wenhui Shi20, Mingzhao Gao21, Yongrong Lai, PhD22
1 National and Kapodistrian University of Athens, Athens, Greece
2 Siriraj Hospital, Mahidol University, Bangkok, Thailand
3 People's Hospital of Liuzhou, Liuzhou, China
4 The 923rd Hospital of the Joint Logistics Support Force of the People's Liberation Army, Nanning, China
5 National Taiwan University Hospital, Taipei, Taiwan
6 Maoming People's Hospital, Maoming, China
7 IRCCS Giannina Gaslini Institute, Genoa, Italy, The FOR ANEMIA ETS Foundation, Genoa, Italy
8 AORN Antonio Cardarelli, Naples, Italy
9 Nanfang Hospital, Southern Medical University, Guangzhou, China
10 Hemoglobinopathies and Rare Blood Disorders Center, San Luigi Gonzaga University Hospital School of Medicine, University of Turin, Turin, Italy
11 Thalassemia and Sickle Cell Unit, Hippokration General Hospital, Athens, Greece
12 Hainan Medical University, Haikou, China
13 Hainan General Hospital, Haikou, China
14 The First People’s Hospital of Foshan, Foshan, China
15 University of Patras, University Hospital, Patras, Greece
16 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
17 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
18 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
19 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
20 Bristol Myers Squibb, Shanghai, China
21 Bristol Myers Squibb, Shanghai, China
22 The First Affiliated Hospital of Guangxi Medical University, Nanning, China

Introduction: α-thalassemia hemoglobin H (HbH) disease results from impaired α-globin chain synthesis, leading to ineffective erythropoiesis and peripheral hemolysis. Patients experience a spectrum of anemia severity and varied transfusion requirement, resulting in a broad range of complications with lifelong effects. Current management for transfusion-dependent (TD) disease mainly includes red blood cell (RBC) transfusions and iron chelation therapy, with significant unmet need for treatments to specifically target the underlying disease pathophysiology. Luspatercept is approved for treating anemia in adults with β-thalassemia. Here, we report primary efficacy and safety data from the TD cohort of a phase 2 trial evaluating luspatercept versus placebo (PBO) in adults with α-thalassemia HbH disease.

Methods: The phase 2, double-blind, randomized, PBO-controlled, multicenter trial (NCT05664737) enrolled adults with a diagnosis of α-thalassemia HbH disease, ECOG performance status score 0 or 1, and TD disease (defined as ≥6 RBC units in the 24 wk prior to randomization). Patients were randomized 2:1 to receive luspatercept (1.0 mg/kg; titration to 1.25 mg/kg allowed) subcutaneously (SC) every 3 wk (Q3W) or PBO SC Q3W for ≥48 wk in the double-blind phase (DBP); randomization was stratified by region (Europe vs Asia) and baseline transfusion burden (TB) (≤6 RBC units vs >6 RBC units [12 wk before randomization]). The primary endpoint was achievement of ≥50% RBC TB reduction and an ≥2 RBC unit decrease from baseline in any continuous 12 wk in wk 13–48 versus the 12 wk before first dose. Key secondary endpoints were ≥33% TB reduction and an ≥2 RBC unit decrease from baseline in any continuous 24 wk, longest duration of ≥50% TB reduction and ≥2 RBC unit decrease, and number of RBC units in wk 1–48. Analyses include data up to the end of the DBP.

Results: As of December 25, 2025, 28 patients were randomized to luspatercept (n=17) or PBO (n=11). Baseline characteristics were generally well balanced between the arms and representative of TD α-thalassemia. Median age in the luspatercept and PBO arms was 30 y and 25 y, 70.6% and 72.7% of patients were female, and median (range) RBC TB (in the 24 wk before first dose) was 10 (6–23) and 8 (6–36) RBC units, respectively. Median treatment duration was 81.3 wk (luspatercept) and 72.6 wk (PBO). Overall, 14 (82.4%) patients receiving luspatercept versus 4 (36.4%) receiving PBO achieved the primary endpoint (difference in response rate, 45.7% [2-sided 95% CI, 6.6–73.5]; P=0.0222). Achievement of ≥33% TB reduction from baseline and ≥2 RBC unit decrease in any 24-wk period was greater with luspatercept versus PBO (94.1% vs 54.5%; difference in response rate, 39.1% [2-sided 95% CI, 5.1–68.4]; P=0.0248). In the luspatercept and PBO groups, 82.4% and 45.5% of patients, respectively, achieved ≥50% TB reduction with an ≥2 RBC unit decrease from baseline (any continuous 12 wk); median duration of response (DOR) was longer with luspatercept (518.5 days vs 181.0 days; ratio of expected DOR, 10.1 [95% CI, 5.1–19.9]; P<0.001). In wk 1–48, significantly fewer median RBC units were received in the luspatercept arm versus PBO (2.00 vs 18.25; least-squares (LS) mean difference, −18.93 [95% CI, −29.03 to −8.83]; P=0.0053). A significantly higher proportion of patients in the luspatercept arm were RBC transfusion-free for any continuous ≥12 wk versus PBO (response rate [95% CI], 88.2% [63.6–98.5] vs 27.3% [6.0–61.0]; nominal P=0.0029). Grade ≥3 treatment-emergent adverse events (TEAEs) occurred in 47.1% and 36.4% patients in the luspatercept and PBO arms, respectively. The most frequent TEAE in the luspatercept arm was upper respiratory tract infection (URTI) (23.5%) and in the PBO was URTI and hemolytic anemia (18.2% each). No treatment-emergent extramedullary hematopoiesis or thromboembolic events, serious treatment-related TEAEs, deaths, or TEAEs leading to death were reported.

Conclusions: Luspatercept achieved statistically significant and clinically meaningful reductions in RBC TB versus PBO in adults with TD α-thalassemia HbH disease, meeting the primary and all key secondary endpoints of the trial. The safety profile of luspatercept was consistent with that in β-thalassemia, with no new safety signals. These findings highlight the favorable benefit–risk profile of luspatercept, supporting its therapeutic potential in adults with TD α-thalassemia HbH disease and addressing an unmet clinical need.
Antonis Kattamis, MD: Amgen - Honoraria; Bristol Myers Squibb - Honoraria; Agios Pharmaceuticals - Honoraria; Avanzanite Bioscience B.V. - Honoraria; Hemanext - Research Funding; Avanzanite Bioscience B.V. - Consultancy (Includes expert testimony); Novo Nordisk - Membership on a Board/Advisory Committee; Bristol Myers Squibb - Membership on a Board/Advisory Committee; Vertex Pharmaceuticals - Membership on a Board/Advisory Committee; Agios Pharmaceuticals - Membership on a Board/Advisory Committee